The Lenacapavir injection drug

Demand for lenacapavir, a long-acting HIV prevention injection given twice a year, has outstripped limited supplies in Uganda, Kenya and Malawi.

Health officials and advocates from the three countries are warning against stirring up demand that health systems cannot meet.

They spoke at a regional webinar on advancing access to lenacapavir for pre-exposure prophylaxis (PrEP) in the three countries.

Warren Mitchell, executive director of AVAC, said the countries reported similar experiences. They stressed developing communication materials with communities, using trusted local voices and folding the injection into broader HIV prevention programmes.

Uganda: more new users than expected

Dr Peter Mudiope, the ministry of Health’s HIV prevention coordinator, said some people who earlier declined other forms of PrEP are now asking for the injection.

“Our initial assumption was to switch people from oral PrEP to LEN, those who were willing. But we realised that some people are not willing to leave oral PrEP. So we have to respect that in the demand generation… We are seeing that there are many more new users of PrEP in the country,” he said.

He said the first rollout showed the need to balance demand creation with supply.

“When we launched PrEP on April 17 this year, we had only 20 doses for the site, and they got finished. Yet we had to reserve the doses for the next six months. We had to call the hospital to come to the launch place. That’s when we realised that we had to promote it as an option…” Mudiope said.

Uganda now has 103 facilities offering lenacapavir and expects more doses in December. Mudiope said the new supply will go first to regions and facilities with very large numbers of people on oral PrEP. Uganda had planned to raise the number of facilities from 103 to 300 by December 2026.

The ministry is urging people to keep using other options while supplies grow. These are daily oral PrEP, the dapivirine vaginal ring and injectable cabotegravir, which is given every two months.

Mudiope said the country is also considering how to position the long-acting products, including whether to keep cabotegravir alongside lenacapavir or reserve it for particular circumstances.

Building trust in communities

Kenneth Mwehonge, executive director of HEPS Uganda, said introducing lenacapavir takes more than awareness campaigns. He urged investment in community structures that can give accurate information, address stigma and misinformation, and link interested people to health facilities.

HEPS worked with communities, local governments and health facilities to train 246 community resource persons from 115 PrEP implementation sites. It also trained 27 national trainers, including ministry of Health staff. Mwehonge said the approach relied on people already trusted in their communities, not parallel structures.

“Communities believe in their peers, and those are the ones, once equipped with the right information, who support in addressing stigma and misinformation. So it has to be a trusted voice within the community,” he said.

The project also supported a revision of Uganda’s PrEP communication strategy to include lenacapavir alongside other prevention products.

The ministry’s communication department reviewed the materials before the Uganda AIDS Commission cleared them. Mwehonge said a lasting lesson is that community mobilisation should be built into existing health structures, so it continues after short-term donor-funded projects end.

Kenya: shortages hurt confidence

Patricia Jeckonia, programme manager for policy, advocacy and HIV prevention at LVCT Health in Kenya, said the Kenyan experience shows how shortages can undermine community confidence when people are urged to seek a product that is not consistently available.

Kenya deliberately built its campaign around PrEP choice rather than lenacapavir alone. It did so after seeing that newer products were affecting uptake of oral PrEP and leaving some people unaware of other options.

Messages were co-created with adolescent girls and young women, pregnant and breastfeeding women, adolescent boys and young men and other priority groups. The programme also recruited social media influencers whom those communities trust.

Even so, supplies ran out quickly. Some people arrived at facilities to find the drug unavailable.

“Every time you had LEN in a facility, it would take two to three days, and it’s over. So that continued. But our demand generation was also very targeted to the counties that were prioritised and around facilities that were providing PrEP choice,” Jeckonia said.

She said Kenya’s experience shows the importance of announcing supply interruptions quickly and helping health workers explain the alternatives to clients.

“Even when there is not yet enough supply, it is very important to empower communities with the right information so that they are aware of what’s available. We give all of the information, but inform them that their supply is not yet enough for now. It’s being rolled out. However, we are also promoting the other options,” she said.

“Demand generation should not be an afterthought. It should be at the very beginning when we are thinking about availability of the product. We should be thinking about how people will know and invest in it,” she said.

Malawi: a phased approach

Simon Sikwese, executive director of Pokachere in Malawi, said the country handed out communication materials in phases to avoid generating demand in districts where lenacapavir was not yet available. He said awareness campaigns must be matched to what health facilities can deliver.

“Ensure that you don’t create demand that you cannot meet. You must look at, for example, in the case of Lenacapavir, how much Lenacapavir you are receiving and how much demand you should create to make sure that you are not exciting people and then, in the end, they don’t access the Lenacapavir,” Sikwese said.

Leave a comment

Your email address will not be published. Required fields are marked *